Project

A phase 3 multicenter, randomized, prospective, open-label trial of ibrutinibmonotherapy versus fixed-duration venetoclax plus obinutuzumab versusfixed-duration ibrutinib plus venetoclax in patients with previously untreatedchronic lymphocytic leukemia (CLL)

Ongoing - recruitment closed · 2021 until 2099

Baumann Michael, Harder Anja, Quinter Janine